/
12 versus 24-hour Bed Rest after Acute Ischemic Stroke Reperfusion Therapy 12 versus 24-hour Bed Rest after Acute Ischemic Stroke Reperfusion Therapy

12 versus 24-hour Bed Rest after Acute Ischemic Stroke Reperfusion Therapy - PowerPoint Presentation

faustina-dinatale
faustina-dinatale . @faustina-dinatale
Follow
365 views
Uploaded On 2020-01-21

12 versus 24-hour Bed Rest after Acute Ischemic Stroke Reperfusion Therapy - PPT Presentation

12 versus 24hour Bed Rest after Acute Ischemic Stroke Reperfusion Therapy Brian Silver MD Tariq Hamid MD Muhib Khan MD Mario DiNapoli MD Reza Behrouz DO Gustavo Saposnik MD JoAnn ID: 773436

bed hour hours rest hour bed rest hours outcome group patients therapy nihss time tpa test physical adjusted thrombolysis

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "12 versus 24-hour Bed Rest after Acute I..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

12 versus 24-hour Bed Rest after Acute Ischemic Stroke Reperfusion Therapy Brian Silver, MD, Tariq Hamid, MD; Muhib Khan, MD; Mario DiNapoli, MD; Reza Behrouz, DO; Gustavo Saposnik, MD; Jo-Ann Sarafin, RNP; Susan Martin, OT; Majaz Moonis, MD; Nils Henninger, MD, PhD; Richard Goddeau, MD; Adalia Jun-O’Connell, MD; Shawna M Cutting, MD, MS; Ali Saad, MD; Shadi Yaghi, MD; Wiley Hall, MD; Susanne Muehlschlegel, MD, MPH; Raphael Carandang, MD; Marcey Osgood, DO; Bradford B. Thompson, MD; Corey R Fehnel, MD; Linda C. Wendell, MD; N. Stevenson Potter, MD; James M Gilchrist, MD; Bruce Barton, PhD

Disclosures Salary: UMassMemorial Medical Center, University of Massachusetts Medical School, Joint Commission (surveyor)Consultant fees: Women’s Health Initiative, Medicolegal malpractice reviewHonoraria: Ebix publishing, MedLink, Medscape

Background The practice of bed rest for ≥24 hours after reperfusion therapy became standard after the NINDS rt-PA trial.Yet, the optimal timing of mobilization in these patients is unknown. Current guidelines recommend against high-dose, very early mobilization within 24 hours of stroke onset as a class III recommendation.

We hypothesized that at a protocol of ≥12 hours bed rest was not inferior to ≥24 hours bed rest following stroke reperfusion therapy. Secondary hypotheses were that rates of pneumonia, venous thromboembolism, and lengths of stay would be reduced in patients in the ≥12 hours bed rest group.Hypothesis

The goal of the study was to compare discharge outcomes among patients who had ≥24 hours bed rest following acute ischemic stroke reperfusion therapy with ≥12 hours bed rest. Goals

Single center RetrospectiveBefore and after (January 27, 2014)Consecutive patientsAdjustments for age, sex, admission NIHSS, time to treatmentAnalyses separated by 1) intravenous thrombolysis only patients, and 2) thrombectomy patients with or without intravenous thrombolysisDesign

Overall (N = 392) ≥24 hour bed rest group (N = 203) ≥12 hour bed rest group (N = 189) P Age (years), mean  +  SD 71.7  +  15.6 71.8  +  15.5 71.5  +  15.9 0.87 Sex (% female) 208 (52.1) 106 (48.0) 102 (54.3) 0.65Race (% white)330 (84.2)172 (84.3)158 (84.0)0.94Race (% black)31 (7.9)17 (8.3)14 (7.4)0.75Ethnicity (% Hispanic)29 (7.4)14 (6.9)15 (8.0)0.67History of hypertension (%)293 (74.7)155 (76.0)138 (73.4)0.56History of prior stroke (%)94 (24.0)40 (19.6)54 (28.7)0.03History of atrial fibrillation (%)104 (26.5)53 (26.0)51 (27.1)0.80History of diabetes (%)96 (24.5)50 (24.5)46 (24.5)0.99History of smoking (%)125 (31.9)63 (30.9)62 (33.0)0.66History of coronary artery disease (%)92 (23.5)54 (26.5)38 (20.2)0.14 Thrombolysis Only patients

  Overall (N = 392) ≥24 hour bed rest group (N = 203) ≥12 hour bed rest group (N = 189) P Median admission NIHSS (IQR) 7 (4-13) 8 (5-13) 7 (4-11) 1.0 Mean time to  tPA from symptom onset, minutes  + SD 146 ± 95 155  +  110 137  +  740.06Mean time to physical therapy documentation from symptom onset, hours + SD50 ± 5759 + 7241 + 300.003Patients with physical therapy documentation < 24 hours from symptom onset (%)47 (15.4)5 (3.1)42 (28.8)<0.0001Mean time to physical therapy documentationfrom first thrombolysis bolus or groin puncture (hours)49 ± 5757 + 7239 + 300.003Patients with physical therapy documentation < 24 hours from first thrombolysis bolus or groin puncture (%)58 (19.0)6 (3.8)52 (35.6)<0.0001Thrombolysis Only patients

Outcome measure ≥24 hour bed rest group (N = 203) ≥12 hour bed rest group (N = 189) P value Unadjusted* P-Value Adjusted** Odds Ratio † (95% CI) Diff:12-24 hr (95% CI) Primary outcome           Favorable discharge¹ (%) 144 (70.9%) 144 (76.2%) 0.24 0.50OR: 1.20(0.71: 2.03)Secondary outcomes     Median NIHSS at 24 hours (IQR)4.5 (2-8)3 (1-7.5)0.0030.008†† Median NIHSS at discharge (IQR)3 (1-7)2 (0-5)0.0040.034†† Mean length of stay (days + SD)5.4 ± 8.83.5  ±  2.70.0040.006Diff: -1.07(-3.22: -0.53)Medical Complications     Venous thromboembolism (%)3 (1.5)1 (0.5)0.340.31OR: 0.30 (0.03: 3.06)Pneumonia (%)17 (8.3)3 (1.6)0.001 0.006 OR: 0.12 (0.03: 0.55) Readmission within 30 days (%) 21 (10.3) 10 (5.3)0.060.054OR: 0.46(0.21: 1.01) ¹Favorable outcome: discharge to home, home with services, or acute rehabilitation.* P-values from likelihood ratio chi-square test for proportions, from standard two-sample two-sided t-test for normally distributed means, and from Wilcoxon rank sum test for non-normally distributed variables.** Adjusted for age (continuous), sex (m/f), admission NIHSS (continuous), tPA received (yes/no: including bolus for endovascular treated patients), endovascular treatment (yes/no), and time to treatment (tPA or time to groin puncture, whichever is first). For medical complications, endovascular treatment could not be used in adjustment due to convergence failure.† Odds ratio for 12 hours relative to 24 hours (OR < 1.0 indicates 12 hour outcome lower than 24 hour outcome); difference for 12 – 24 hour outcome (difference < 0.0 indicates 12 hour outcome lower than 24 hour outcome)†† Adjusted p-value for van Elteren non-parametric test to compare non-normal continuous outcomes (NIHSS) between assigned bedtime adjusted for covariates: sex, NIHSS at admission. Resulting score statistic not presented. Thrombolysis Only patients

  Overall (N = 193) ≥24 hour bed rest group (N = 59) ≥12 hour bed rest group (N = 134) P Age (years), mean  +  SD 72.2  +  16.0 71.9  +  16.1 72.4  +  16.0 0.85 Sex (% female) 95 (49.2) 22 (37.3) 73 (54.5)0.03Race (% white)156 (80.8)49 (83.1)107 (79.9)0.60Race (% black)17 (8.8)4 (6.8)13 (9.7)0.50Ethnicity (% Hispanic)8 (4.2)5 (8.5)3 (2.2)0.06History of hypertension (%)136 (70.5)42 (71.2)94 (70.2)0.88History of prior stroke (%)35 (18.1)7 (11.9)28 (20.9)0.12History of atrial fibrillation (%)64 (33.2)16 (27.1)48 (35.8)0.23History of diabetes (%)41 (21.2)11 (18.6)30 (22.4)0.55History of smoking (%)51 (26.4)17 (28.8)34 (25.4)0.62History of coronary artery disease (%)47 (24.4)13 (22.0) 34 (25.4) 0.62 Thrombectomy Patients (with/without tPA )

  Overall (N = 193) ≥24 hour bed rest group (N = 59) ≥12 hour bed rest group (N = 134) P* Median admission NIHSS (IQR) 18 (12-23) 18 (14-23) 17 (12-22) 1.0 Received  tPA (%) 172 (89.1) 59 (100.0) 113 (84.3) <0.0001 Mean time to groin puncture from symptom onset, minutes ± SD 168 ± 94 160 ± 107 171 ± 87 0.45Mean time to physical therapy documentation from symptom onset, hours + SD47 ± 4378 + 6538 + 210.0002Patients with physical therapy documentation < 24 hours from symptom onset (%)34 (22.5)1 (2.3)33 (30.8)<0.0001Mean time to physical therapy documentation from first thrombolysis bolus or groin puncture (hours)47 ± 4376 + 6535 + 210.0001Patients with physical therapy documentation < 24 hours from first thrombolysis bolus or groin puncture (%)45 (29.8)1 (2.3)44 (41.1)<0.0001Thrombectomy Patients (with/without tPA)

Outcome measure ≥24 hour bed rest group (N =59) ≥12 hour bed rest group (N = 134) P value Unadjusted* P-Value Adjusted** Odds Ratio † (95% CI) Diff:12-24 hr (95% CI) Primary outcome           Favorable discharge¹ (%) 32 (54.2) 92 (68.7) 0.056 0.14OR: 1.73(0.84: 3.56)Secondary outcomes     Median NIHSS at 24 hours (IQR)12 (7-18)8 (4-14)0.0130.024†† Median NIHSS at discharge (IQR)8 (4-14)4 (2-9)0.0040.036†† Mean length of stay (days + SD)7.5 ± 6.13.9 ± 3.3<0.0001<0.0001Diff: -3.45(-4.82: -2.03)Medical Complications     Venous thromboembolism (%)1 (1.7)0 (0.0)0.120.31--Pneumonia (%)8 (13.6)5 (3.7) 0.017 0.030 OR: 0.27 (0.08: 0.88) Readmission within 30 days (%) 6 (10.2)3 (2.2)0.0220.017 OR: 0.16(0.04: 0.72)¹Favorable outcome: discharge to home, home with services, or acute rehabilitation.* P-values from likelihood ratio chi-square test for proportions, from standard two-sample two-sided t-test for normally distributed means, and from Wilcoxon rank sum test for non-normally distributed variables. ** Adjusted for age (continuous), sex (m/f), admission NIHSS (continuous), tPA received (yes/no: including bolus for endovascular treated patients), endovascular treatment (yes/no), and time to treatment ( tPA or time to groin puncture, whichever is first). For medical complications, endovascular treatment could not be used in adjustment due to convergence failure. † Odds ratio for 12 hours relative to 24 hours (OR < 1.0 indicates 12 hour outcome lower than 24 hour outcome); difference for 12 – 24 hour outcome (difference < 0.0 indicates 12 hour outcome lower than 24 hour outcome) †† Adjusted p-value for van Elteren non-parametric test to compare non-normal continuous outcomes (NIHSS) between assigned bedtime adjusted for covariates: sex, NIHSS at admission. Resulting score statistic not presented. Thrombectomy Patients (with/without tPA )

Compared with ≥24 hour bed rest, ≥12 hour bed rest after acute ischemic stroke reperfusion therapy appeared to be safe and may be associated with reduced neurological deficit at discharge, shorter length-of-stay, and reduced rates of readmission within 30 days. A randomized trial is needed to verify these findings.Conclusions